Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Protein Kinase Inhibitors"" wg kryterium: Temat


Tytuł:
BCL-X L inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF colorectal cancer.
Autorzy:
Jenkins LJ; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
Luk IY; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
Chionh F; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
Tan T; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia.
Needham K; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
Ayton J; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
Reehorst CM; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
Vukelic N; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
Sieber OM; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia.; Department of Surgery, The University of Melbourne, Melbourne, VIC, Australia.; Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, Australia.
Mouradov D; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia.
Gibbs P; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Williams DS; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.; Department of Pathology, Austin Health, Melbourne, VIC, Australia.
Tebbutt NC; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; Department of Surgery, The University of Melbourne, Melbourne, VIC, Australia.; Department of Medical Oncology, Austin Health, Melbourne, Australia.
Desai J; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Hollande F; Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, Australia.; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Melbourne, VIC, Australia.
Dhillon AS; The institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University, Geelong, Australia.
Lee EF; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.; Department of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, Australia.
Merino D; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia.; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Fairlie WD; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.; Department of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, Australia.
Mariadason JM; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia. .; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia. .
Pokaż więcej
Źródło:
Cell death & disease [Cell Death Dis] 2024 Mar 01; Vol. 15 (3), pp. 183. Date of Electronic Publication: 2024 Mar 01.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
bcl-X Protein*/antagonists & inhibitors
bcl-X Protein*/metabolism
Carbamates*
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Apoptosis*/drug effects
Animals ; Humans ; Mice ; Myeloid Cell Leukemia Sequence 1 Protein/genetics ; Myeloid Cell Leukemia Sequence 1 Protein/metabolism ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors ; Proto-Oncogene Proteins B-raf/genetics ; Sulfonamides/pharmacology ; Sulfonamides/therapeutic use
Czasopismo naukowe
Tytuł:
ZNL0325, a Pyrazolopyrimidine-Based Covalent Probe, Demonstrates an Alternative Binding Mode for Kinases.
Autorzy:
Li Z; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, California 94305, United States.
Lu W; Lingang Laboratory, Shanghai 200031, China.
Beyett TS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
Ficarro SB; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Blais Proteomics Center, Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02215, United States.
Jiang J; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, United States.
Tse J; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, California 94305, United States.
Kim AY; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, California 94305, United States.
Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Blais Proteomics Center, Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02215, United States.
Che J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
Jänne PA; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, United States.
Eck MJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
Zhang T; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, California 94305, United States.
Gray NS; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, California 94305, United States.
Pokaż więcej
Źródło:
Journal of medicinal chemistry [J Med Chem] 2024 Feb 22; Vol. 67 (4), pp. 2837-2848. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/chemistry
Protein Kinases*/metabolism
Adenosine Triphosphate
Czasopismo naukowe
Tytuł:
Generating Potential RET-Specific Inhibitors Using a Novel LSTM Encoder-Decoder Model.
Autorzy:
Liu L; Institute of Theoretical Chemistry, College of Chemistry, Jilin University, Changchun 130061, China.
Zhao X; Institute of Theoretical Chemistry, College of Chemistry, Jilin University, Changchun 130061, China.
Huang X; Institute of Theoretical Chemistry, College of Chemistry, Jilin University, Changchun 130061, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 17; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 17.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/chemistry
Proto-Oncogene Proteins c-ret*/antagonists & inhibitors
Humans ; Molecular Dynamics Simulation
Czasopismo naukowe
Tytuł:
Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.
Autorzy:
Ezzati S; California Northstate University College of Medicine, Elk Grove, CA 95757, USA.
Salib S; California Northstate University College of Medicine, Elk Grove, CA 95757, USA.
Balasubramaniam M; Reynolds Institute on Aging, Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Aboud O; Department of Neurology, Department of Neurological Surgery, Comprehensive Cancer Center, University of California, Davis, Sacramento, CA 95817, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 15; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 15.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Brain Neoplasms*/drug therapy
ErbB Receptors*/antagonists & inhibitors
Glioblastoma*/drug therapy
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Adult ; Humans ; Precision Medicine ; Signal Transduction
Czasopismo naukowe
Tytuł:
Identification of New EGFR Inhibitors by Structure-Based Virtual Screening and Biological Evaluation.
Autorzy:
Wang S; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Xu X; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Pan C; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Guo Q; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Li Q; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Wan S; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Li Z; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Zhang J; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Wu X; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 04; Vol. 25 (3). Date of Electronic Publication: 2024 Feb 04.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/chemistry
Antineoplastic Agents*/isolation & purification
Antineoplastic Agents*/pharmacology
ErbB Receptors*/antagonists & inhibitors
Protein Kinase Inhibitors*/chemistry
Protein Kinase Inhibitors*/isolation & purification
Protein Kinase Inhibitors*/pharmacology
Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Cell Line, Tumor ; Cell Proliferation ; Lung Neoplasms/drug therapy ; Molecular Docking Simulation ; Molecular Dynamics Simulation
Czasopismo naukowe
Tytuł:
Degradation trumps mutations in cancer.
Autorzy:
Davis RE; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
Westin JR; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2024 Feb 02; Vol. 383 (6682), pp. 480-481. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Resistance, Neoplasm*/drug effects
Drug Resistance, Neoplasm*/genetics
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Proteolysis*/drug effects
Cell Line, Tumor ; Mutation ; Humans
Czasopismo naukowe
Tytuł:
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Autorzy:
Montoya S; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Bourcier J; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Noviski M; Nurix Therapeutics, San Francisco, CA, USA.
Lu H; Nurix Therapeutics, San Francisco, CA, USA.
Thompson MC; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chirino A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Jahn J; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Sondhi AK; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Gajewski S; Nurix Therapeutics, San Francisco, CA, USA.
Tan YSM; Nurix Therapeutics, San Francisco, CA, USA.
Yung S; Nurix Therapeutics, San Francisco, CA, USA.
Urban A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Wang E; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Han C; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Mi X; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kim WJ; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sievers Q; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Auger P; Nurix Therapeutics, San Francisco, CA, USA.
Bousquet H; Nurix Therapeutics, San Francisco, CA, USA.
Brathaban N; Nurix Therapeutics, San Francisco, CA, USA.
Bravo B; Nurix Therapeutics, San Francisco, CA, USA.
Gessner M; Nurix Therapeutics, San Francisco, CA, USA.
Guiducci C; Nurix Therapeutics, San Francisco, CA, USA.
Iuliano JN; Nurix Therapeutics, San Francisco, CA, USA.
Kane T; Nurix Therapeutics, San Francisco, CA, USA.
Mukerji R; Nurix Therapeutics, San Francisco, CA, USA.
Reddy PJ; Nurix Therapeutics, San Francisco, CA, USA.
Powers J; Nurix Therapeutics, San Francisco, CA, USA.
Sanchez Garcia de Los Rios M; Nurix Therapeutics, San Francisco, CA, USA.
Ye J; Nurix Therapeutics, San Francisco, CA, USA.
Barrientos Risso C; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Tsai D; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Pardo G; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Notti RQ; Laboratory of Molecular Electron Microscopy, Rockefeller University, New York, NY, USA.
Pardo A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Affer M; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Nawaratne V; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Totiger TM; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Pena-Velasquez C; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rhodes JM; Division of Hematology-Oncology, Department of Medicine at Zucker School of Medicine at Hofstra/Northwell, CLL Research and Treatment Center, Lake Success, NY, USA.
Zelenetz AD; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alencar A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Roeker LE; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mehta S; Gene Editing and Screening Core Facility, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Institute and Cancer Center, New York, NY, USA.
Garippa R; Gene Editing and Screening Core Facility, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Institute and Cancer Center, New York, NY, USA.
Linley A; Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Soni RK; Proteomics and Macromolecular Crystallography Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
Skånland SS; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Brown RJ; Nurix Therapeutics, San Francisco, CA, USA.
Mato AR; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hansen GM; Nurix Therapeutics, San Francisco, CA, USA.
Abdel-Wahab O; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Taylor J; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2024 Feb 02; Vol. 383 (6682), pp. eadi5798. Date of Electronic Publication: 2024 Feb 02.
Typ publikacji:
Journal Article
MeSH Terms:
Agammaglobulinaemia Tyrosine Kinase*/genetics
Agammaglobulinaemia Tyrosine Kinase*/metabolism
Ikaros Transcription Factor*/metabolism
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Proteolysis*/drug effects
Drug Resistance, Neoplasm*/drug effects
Humans ; Mutation ; Phosphorylation ; Signal Transduction
Czasopismo naukowe
Tytuł:
Synergy and antagonism between azacitidine and FLT3 inhibitors.
Autorzy:
Yang J; Department of Chemistry and Biomedical Science, Linnaeus University, Kalmar, SE-39231, Sweden.
Friedman R; Department of Chemistry and Biomedical Science, Linnaeus University, Kalmar, SE-39231, Sweden. Electronic address: .
Pokaż więcej
Źródło:
Computers in biology and medicine [Comput Biol Med] 2024 Feb; Vol. 169, pp. 107889. Date of Electronic Publication: 2023 Dec 21.
Typ publikacji:
Journal Article
MeSH Terms:
Amides*
Aniline Compounds*/pharmacology
Aniline Compounds*/therapeutic use
Azacitidine*/pharmacology
Azacitidine*/therapeutic use
Benzothiazoles*
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Phenylurea Compounds*
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Pyrazines*
Pyrimidines*
Humans ; fms-Like Tyrosine Kinase 3/genetics ; fms-Like Tyrosine Kinase 3/therapeutic use ; Mutation
Czasopismo naukowe
Tytuł:
Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers.
Autorzy:
Shan KS; Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA.
Rehman TU; Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA.
Ivanov S; Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA.
Domingo G; Memorial Health Care, Division of Hematology and Oncology, Pembroke Pines, FL 33328, USA.
Raez LE; Memorial Health Care, Thoracic Oncology Program, Pembroke Pines, FL 33328, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 03; Vol. 25 (1). Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Melanoma*/drug therapy
Melanoma*/genetics
Protein Kinase Inhibitors*/pharmacology
Protein Kinase Inhibitors*/therapeutic use
Humans ; Mitogen-Activated Protein Kinase Kinases ; Mitogen-Activated Protein Kinases ; Molecular Targeted Therapy ; Proto-Oncogene Proteins B-raf/genetics
Czasopismo naukowe
Tytuł:
Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases.
Autorzy:
Roskoski R Jr; Blue Ridge Institute for Medical Research, 221 Haywood Knolls Drive, Hendersonville, NC 28791, United States. Electronic address: .
Pokaż więcej
Źródło:
Pharmacological research [Pharmacol Res] 2024 Jan; Vol. 199, pp. 107036. Date of Electronic Publication: 2023 Dec 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Protein Kinase Inhibitors*/therapeutic use
Protein Kinase Inhibitors*/pharmacology
Neoplasms*/drug therapy
Neoplasms*/metabolism
Humans ; United States
Czasopismo naukowe
Tytuł:
Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center.
Autorzy:
Kennedy A; Tufts Medical Center, Department of Internal Medicine, Boston, MA, USA.; University of Massachusetts Chan Medical School, Worcester, MA, USA.
Patel S; Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, Worcester, MA, USA.
Ramanathan M; Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, Worcester, MA, USA.
Gerber J; Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, Worcester, MA, USA.
Cerny J; Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, Worcester, MA, USA. .
Pokaż więcej
Źródło:
Annals of hematology [Ann Hematol] 2024 Mar; Vol. 103 (3), pp. 1031-1033. Date of Electronic Publication: 2024 Jan 09.
Typ publikacji:
Letter
MeSH Terms:
Protein Kinase Inhibitors*
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Staurosporine/*analogs & derivatives
Humans ; Staurosporine/therapeutic use ; fms-Like Tyrosine Kinase 3/genetics ; Mutation
Opinia redakcyjna
Tytuł:
Inhibition of the Rho/ROCK pathway promotes the expression of developmental and migration-related genes in astrocytes exposed to alcohol.
Autorzy:
Xunzhong Q; Department of Neurology, The First Affiliated Hospital of Jiamusi University, Jiamusi, People's Republic of China.
Miao G; Jiamusi University, Jiamusi, People's Republic of China.
Guangtao S; Department of Neurology, The First Affiliated Hospital of Jiamusi University, Jiamusi, People's Republic of China.
Huiying Z; Department of Neurology, Yichun Forestry Administration Central Hospital, Yichun, People's Republic of China.
Chenglong H; Department of Clinical Laboratory, University-Town Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Xiaogang Z; NHC Key Laboratory of Diagnosis and Treatment on Brain Functional Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China; College of Basic Medicine, Chongqing Medical University, Chongqing, People's Republic of China.
Shunjie B; Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Xinyan H; The Second Affiliated Hospital of Jiamusi University, Jiamusi, People's Republic of China.
Chengji W; Department of Neurology, The First Affiliated Hospital of Jiamusi University, Jiamusi, People's Republic of China.
Zuoyi H; Department of Neurology, The First Affiliated Hospital of Jiamusi University, Jiamusi, People's Republic of China. Electronic address: huangzuoyi_.
Xiaofeng Z; Mudanjiang Medical College, Mudanjiang, People's Republic of China. Electronic address: zhuxiaofeng_.
Pokaż więcej
Źródło:
Alcohol (Fayetteville, N.Y.) [Alcohol] 2024 Mar; Vol. 115, pp. 5-12. Date of Electronic Publication: 2023 Jul 20.
Typ publikacji:
Journal Article
MeSH Terms:
Astrocytes*/metabolism
Protein Kinase Inhibitors*/pharmacology
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/*analogs & derivatives
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/pharmacology ; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/metabolism ; Ethanol/pharmacology
Czasopismo naukowe
Tytuł:
Ponatinib-induced desquamation-Unifying eponymous terminology for a rare adverse event.
Autorzy:
Danish M; Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, New Delhi, India.
Patel V; Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, New Delhi, India.
Arava S; Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Ahuja R; Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, New Delhi, India.
Pokaż więcej
Źródło:
Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Mar; Vol. 38 (3), pp. e247-e249. Date of Electronic Publication: 2023 Oct 16.
Typ publikacji:
Letter
MeSH Terms:
Protein Kinase Inhibitors*
Imidazoles*
Pyridazines*
Humans
Opinia redakcyjna
Tytuł:
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies.
Autorzy:
Robbins DW; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Noviski MA; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Tan YS; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Konst ZA; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Kelly A; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Auger P; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Brathaban N; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Cass R; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Chan ML; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Cherala G; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Clifton MC; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Gajewski S; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Ingallinera TG; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Karr D; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Kato D; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Ma J; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
McKinnell J; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
McIntosh J; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Mihalic J; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Murphy B; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Panga JR; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Peng G; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Powers J; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Perez L; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Rountree R; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Tenn-McClellan A; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Sands AT; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Weiss DR; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Wu J; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Ye J; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Guiducci C; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Hansen G; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Cohen F; Nurix Therapeutics, Inc., 1700 Owens St., San Francisco, California 94158, United States.
Pokaż więcej
Źródło:
Journal of medicinal chemistry [J Med Chem] 2024 Feb 22; Vol. 67 (4), pp. 2321-2336. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Protein-Tyrosine Kinases*
Protein Kinase Inhibitors*/adverse effects
Humans ; Agammaglobulinaemia Tyrosine Kinase ; Signal Transduction
Czasopismo naukowe
Tytuł:
Synthesis and biological evaluation of 1H-pyrrolo[3,2-g]isoquinolines.
Autorzy:
Defois M; Université Clermont Auvergne, CNRS, Clermont Auvergne INP, ICCF, F-63000 Clermont-Ferrand, France.
Josselin B; Sorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, 29680 Roscoff, France; Sorbonne Université, CNRS, FR2424, Plateforme de criblage KISSf (Kinase Inhibitor Specialized Screening facility), Station Biologique de Roscoff, 29680 Roscoff, France.
Brindeau P; Sorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, 29680 Roscoff, France.
Krämer A; Institute of Pharmaceutical Chemistry, Johann Wolfgang Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany; Frankfurt Cancer Institute, Goethe University, Frankfurt am Main, Germany.
Knapp S; Institute of Pharmaceutical Chemistry, Johann Wolfgang Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany; Frankfurt Cancer Institute, Goethe University, Frankfurt am Main, Germany.
Anizon F; Université Clermont Auvergne, CNRS, Clermont Auvergne INP, ICCF, F-63000 Clermont-Ferrand, France.
Giraud F; Université Clermont Auvergne, CNRS, Clermont Auvergne INP, ICCF, F-63000 Clermont-Ferrand, France. Electronic address: .
Ruchaud S; Sorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, 29680 Roscoff, France. Electronic address: .
Moreau P; Université Clermont Auvergne, CNRS, Clermont Auvergne INP, ICCF, F-63000 Clermont-Ferrand, France. Electronic address: .
Pokaż więcej
Źródło:
Bioorganic & medicinal chemistry [Bioorg Med Chem] 2024 Feb 15; Vol. 100, pp. 117619. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Protein Kinase Inhibitors*/chemistry
Pyrroles*/chemistry
Protein Serine-Threonine Kinases*/antagonists & inhibitors
Structure-Activity Relationship ; Isoquinolines/chemistry ; Isoquinolines/pharmacology
Czasopismo naukowe
Tytuł:
Ultrasensitive detection of imatinib in human serum using a gold-based paper sensor.
Autorzy:
Jiang X; State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, People's Republic of China; International Joint Research Laboratory for Biointerface and Biodetection, and School of Food Science and Technology, Jiangnan University, Wuxi, People's Republic of China.
Qu A; State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, People's Republic of China; International Joint Research Laboratory for Biointerface and Biodetection, and School of Food Science and Technology, Jiangnan University, Wuxi, People's Republic of China.
Xu X; State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, People's Republic of China; International Joint Research Laboratory for Biointerface and Biodetection, and School of Food Science and Technology, Jiangnan University, Wuxi, People's Republic of China.
Kuang H; State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, People's Republic of China; International Joint Research Laboratory for Biointerface and Biodetection, and School of Food Science and Technology, Jiangnan University, Wuxi, People's Republic of China.
Liu L; State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, People's Republic of China; International Joint Research Laboratory for Biointerface and Biodetection, and School of Food Science and Technology, Jiangnan University, Wuxi, People's Republic of China. Electronic address: .
Xu C; State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, People's Republic of China; International Joint Research Laboratory for Biointerface and Biodetection, and School of Food Science and Technology, Jiangnan University, Wuxi, People's Republic of China.
Pokaż więcej
Źródło:
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences [J Chromatogr B Analyt Technol Biomed Life Sci] 2024 Feb 15; Vol. 1234, pp. 124001. Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:
Journal Article
MeSH Terms:
Tandem Mass Spectrometry*
Protein Kinase Inhibitors*
Humans ; Imatinib Mesylate ; Chromatography, Liquid ; Immunoassay/methods ; Gold Colloid/chemistry ; Limit of Detection ; Chromatography, Affinity/methods
Czasopismo naukowe
Tytuł:
How to improve treatment-free remission eligibility in chronic myeloid leukaemia?
Autorzy:
Costa A; Hematology Unit, Department of Medical Sciences and Public Health, Businco Hospital, University of Cagliari, Cagliari, Italy.
Breccia M; Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy.
Pokaż więcej
Źródło:
British journal of haematology [Br J Haematol] 2024 Feb; Vol. 204 (2), pp. 434-448. Date of Electronic Publication: 2023 Dec 26.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Protein Kinase Inhibitors*/therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy
Humans ; Remission Induction ; Neoplasm Recurrence, Local/drug therapy ; Risk Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Design, synthesis, molecular docking and biological evaluation of 1,3,5-trisubstituted-1H-pyrazole derivatives as anticancer agents with cell cycle arrest, ERK and RIPK3- kinase activities.
Autorzy:
Boshta NM; Chemistry Department, Faculty of Science, Menoufia University, Shebin El-Koam 32511, Egypt. Electronic address: .
Temirak A; Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, Giza 12622, Egypt. Electronic address: .
El-Shahid ZA; Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, Giza 12622, Egypt.
Shafiq Z; Institute of Chemical Sciences, Bahauddin Zakariya University, Multan, Pakistan.
Soliman AAF; Drug Bioassay-Cell Culture Laboratory, Pharmacognosy Department, National Research Center, Giza 12622, Egypt.
Pokaż więcej
Źródło:
Bioorganic chemistry [Bioorg Chem] 2024 Feb; Vol. 143, pp. 107058. Date of Electronic Publication: 2023 Dec 28.
Typ publikacji:
Journal Article
MeSH Terms:
Protein Kinase Inhibitors*
Antineoplastic Agents*/chemistry
Humans ; Molecular Docking Simulation ; Cell Cycle Checkpoints ; Pyrazoles/chemistry ; Cell Proliferation ; Cell Line, Tumor ; Drug Screening Assays, Antitumor ; Structure-Activity Relationship ; Molecular Structure ; Receptor-Interacting Protein Serine-Threonine Kinases/metabolism ; Receptor-Interacting Protein Serine-Threonine Kinases/pharmacology
Czasopismo naukowe
Tytuł:
Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study.
Autorzy:
Lei J; Department of Pediatric Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Wang W; Department of Pediatric Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Lin D; Department of Pediatric Hematology and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China.
Zhu C; Department of Pediatric Hematology and Oncology, Hunan Provincial People's Hospital, Changsha, 410005, China.
Jia W; The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.
Weng W; Department of Pediatric Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Liu X; Department of Pediatric Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Ma Y; Department of Pediatric Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Wang Z; Department of Pediatric Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Yang L; Department of Pediatric Hematology and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China. .
He X; Department of Pediatric Hematology and Oncology, Hunan Provincial People's Hospital, Changsha, 410005, China. .
He Y; The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China. .
Li Y; Department of Pediatric Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. .
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Jan 17; Vol. 150 (1), pp. 12. Date of Electronic Publication: 2024 Jan 17.
Typ publikacji:
Multicenter Study; Observational Study; Journal Article
MeSH Terms:
Proto-Oncogene Proteins B-raf*/genetics
Protein Kinase Inhibitors*/therapeutic use
Humans ; Child ; Vemurafenib ; Combined Modality Therapy ; Mutation
Czasopismo naukowe
Tytuł:
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L.
Autorzy:
Wang X; Department of Biochemistry and Molecular Biology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
DeFilippis RA; Division of Hematology/Oncology, University of California, San Francisco, CA, USA.
Weldemichael T; Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Gunaganti N; Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Tran P; Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Leung YK; Department of Pharmacology & Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Shah NP; Division of Hematology/Oncology, University of California, San Francisco, CA, USA.
Li HY; Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: .
Pokaż więcej
Źródło:
European journal of medicinal chemistry [Eur J Med Chem] 2024 Jan 15; Vol. 264, pp. 115977. Date of Electronic Publication: 2023 Nov 25.
Typ publikacji:
Journal Article
MeSH Terms:
Protein Kinase Inhibitors*/chemistry
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/metabolism
Humans ; Molecular Docking Simulation ; Mutation ; Pyridines/therapeutic use ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies